Product Description:

TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic “death domain”, which activates the cell’s apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain. Recombinant Human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF-homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein.

Technical Specifications:

• Species: Human
• Expression: E. coli Cell Expressed
• Activity:
  • Assay 1: Typically 1-3 ng/mL ED50
  • Typically 0.8-2.0 ng/mL ED50
• Purity: ≥98%
• Endotoxin: <1.0 EU/μg
• Molecular Mass: 19.6 kDa
• Formulation: 1x PBS
• Country of Origin: USA

Purity Confirmation:

This was determined by SDS-PAGE gel and HPLC analysis.

Activity Assay:

Assay#1: Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells.

Assay#2: Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells).

AA Sequence:

Reconstitution Buffer:

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.5-1.0 mg/ml. Do not vortex.

Storage:

For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% HSA) and store in working aliquots at -20°C to -80°C.